LOGIN
ID
PW
MemberShip
2026-03-16 23:45:10
All News
Policy
Company
Product
Opinion
InterView
검색
Dailypharm Live Search
Close
Company
The flu is going around in the southern hemisphere
by
Whang, byung-woo
Jun 27, 2022 05:57am
Concerns are growing that the influenza epidemic may begin as the COVID-19 pandemic turns into an endemic and social distancing such as lifting outdoor masks is eased. As the flu is showing signs of a full-fledged epidemic in Australia, one of the southern hemisphere countries that uses the flu as an indicator of the flu epidemic in the second half of the year, concerns are also being raised. It is pointed out that it is necessary to prepare countermeasures as the flu vaccination rate has fallen due to the influence of the COVID-19 pandemic over the past two years, and there may be repercussions from the release of masks. In the case of the flu epidemic, the epidemic scenario in the northern hemisphere is often calculated based on the situation in the southern hemisphere in the first half of the year. As winter comes first in the southern hemisphere, it is to guess the trend of infectious diseases. According to the Australian Influenza Surveillance Report (AISR), published biweekly by the Department of Health, the number of patients with flu symptoms in Australia has increased since March this year. In May, Australia's medical institutions confirmed influenza viruses in samples such as patient sputum and runny nose and reported more than 25,000 cases to the Ministry of Health per week, and by early June, 87,989 cases were reported to Australia's NNDSS, of which 47,860 occurred in late May and early June. This is a rapid increase compared to data from the past five years, and the gap is wider considering that the flu epidemic has not occurred due to COVID-19 in the past two years. In the end, it is pointed out that the same phenomenon may occur during the domestic flu epidemic in the second half of the year. Jung, Ki-seok, a professor of respiratory medicine at Hallym University Sungsim Hospital, said, "I don't know how much more exchanges between countries will occur in the second half, but I think the domestic flu will be the same." He said, "It is also difficult to predict the presence or absence of new mutations in COVID-19, but I think it is highly likely to be prevalent once more." Choi Young-joon, general director of the KSPID (Korea University's Department of Pediatrics and Adolescents), also said, "We say that the epidemic will be this year because we haven't caught much flu over the past two years," adding, "There has been no local transmission and there is a high possibility of infection." Companies such as Pfizer and Moderna have started to develop Combo vaccines that inoculate flu vaccines and COVID-19 vaccines at once, but as they have not yet succeeded in developing them, it is also the best countermeasure to plan individual vaccination plans at this stage. During the COVID-19 pandemic, the number of vaccinations increased significantly due to concerns over twin-demic during the 2020 vaccination period, but the site explained that NIP-oriented flu vaccinations were made in 2021. Vice Chairman of the KIES Shin Kwang-chul said, "In 2020, I have been vaccinated the most and I remember securing as many flu vaccines as possible," adding, "But last year, we set the demand for flu vaccines low enough to order only 30% of the quantity in 2020." With the possibility of a flu epidemic, companies that produce flu vaccines are also getting busy. As SK Bioscience has not produced a flu vaccine this year following last year, domestic companies and multinational pharmaceutical companies are filling it up. Sanofi Pasteur has already submitted to supply 2.2 million doses per dose at 10, 433 won per dose in connection with the procurement of the national vaccination (free flu vaccine vaccination project) for influenza vaccines, and has been selected as the top priority. 3 million doses of flu vaccine for Ilyang Pharmaceutical, which previously included NIP, are expected to be vaccinated in the private market. Already on the 18th of last month, U.S. health authorities began discussing ways to vaccinate flu and coronavirus at the same time in preparation for the simultaneous spread of COVID-19 and flu in winter. There are negative opinions due to concerns over the stability of vaccinating two vaccines, but we cannot ignore the situation in which twin-demise will occur. Domestic experts also say that it is necessary to consider temporarily expanding the scope of NIP as well as vaccinating COVID-19 and flu vaccines at the same time. Professor Jeong said, "There will be no big problem because the guidelines have already been set for inoculating two types of vaccines with one arm on each side." "If the flu vaccine epidemic is expected, we think it will be necessary to think about expanding the NIP range as we did before," he said.
Company
Sanofi’s Allegra dominates OTC·ETC drug market
by
Nho, Byung Chul
Jun 24, 2022 05:46am
The market for OTCs and ETCs of the antihistamine ingredient fexofenadine hydrochloride has been showing stagnant performance with its sales making a rectangle pattern for several years now. The market is virtually monopolized by the original drug, Sanofi’s Allegra Tab., with the total market estimated to be in the ₩8 billion range. One aspect to note is that the high-dose 120mg Allegra Tab. is listed for reimbursement as an OTC, and the other 180·60·30mg strengths of Allegra are distributed and prescribed as ETCs in Korea. This is analyzed as a strategic decision made by the company in consideration of the clinical protocol, design, and efficacy of its drug. Allegra is in the undisputed lead among fexofenadine hydrochloride OTCs, showing a vendor performance of ₩2-3 billion. Hanmi Pharmaceutical's Fexonadine, Huon’s Allerdin, and Chong Kun Dang’s Pecsone 120mg had sold ₩350 million, ₩150 million, and 120 million each, respectively. These latecomers were all released around 2005 and 2008, and all three drugs are all listed at ₩226 per tablet. The price of Sanofi’s finished imported pharmaceutical, the OTC Allegra, has been discounted to ₩225/tablet in 2017, ₩224/tablet in 2018, then to ₩222 in 2022, and is currently sold at a lower price than its domestic latecomers. Allegra and other OTC drugs with identical APIs that are effective in alleviating symptoms of allergic rhinitis are recommended to be administered with caution in patients with kidney failure, cardiovascular disease, or old age, and require particular medication guidance on the pharmacist’s part. In addition, its related ingredients are classified as pregnancy risk category C, and are used when there is a clear clinical basis or reason for its inevitable use. In the fexofenadine hydrochloride ETC market, the original, Sanofi’s Allegra and its bioequivalent, Hanmi Pharmaceutical’s Fexonadine are in a two-way battle. Allegra 180mg sold ₩3.1 billion, Fexonadine 180mg ₩870 million last year, and Allegra 30mg ₩240 million, Fexonadine 30mg ₩140 million. The 180mg strength of Allegra that was approved in 2000 is used to treat allergic dermatitis, and its price had been reduced to ₩314/tablet in 2017, ₩313/tablet in 2018, ₩312/tablet in 2020, and then to ₩311/tablet in 2022. The price of Allegra 60mg is currently set at ₩181/tablet and is effective in relieving symptoms of seasonal allergic rhinitis. According to the insert paper, etc. patients with hypertension, diabetic kidney disease, hyperthyroidism, and benign prostatic hyperplasia are requested to consult with their doctor, dentist, or pharmacist before taking the drug. Allegra 30mg, which is priced at ₩91/tablet, is prescribed to relieve symptoms of seasonal allergic rhinitis and allergic dermatitis. Hanmi Pharmaceutical’s Fexonadine 30mg, which was approved as a bioequivalence-assured product in 2007 is listed at ₩91/tablet, at the same price as the original drug. Meanwhile, one point of interest is in their distribution. The distribution of Allegra is dualized so that the OTCs are directly managed by Sanofi while the ETCs are imported and sold by Handok Pharmaceuticals.
Company
Yuhan’s new lung cancer drug Leclaza shows OS benefit
by
Nho, Byung Chul
Jun 24, 2022 05:46am
Yuhan Corp (CEO and President Wook Je Cho) announced on the 23rd that it had confirmed the overall survival (OS) benefit of Leclaza (lasertinib) in the Phase I/II LASER201 trial (NCT03046992). Leclaza is a treatment for epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC). Leclaza is a third-generation oral EGFR Tyrosine Kinase Inhibitor (TKI) that has high selectivity against the EGFR T790M resistant mutation. The drug showed superior efficacy and safety in NSCLC patients with brain metastasis as it can pass through the blood-brain-barrier (BBB). Lecalza’s OS results had been presented at the AOS 2022 & KCA Annual Meeting 2022 which was held from the 16th to 18th of this month. The OS results were updated from the Phase I/II LASER201 trial that had been the basis for Leclaza’s approval in Korea. The Phase I/II trial evaluated the efficacy and safety of continuous daily oral administration of Leclaza 240mg on 78 adult patients with EGFR mutation-positive NSCLC whose disease had progressed after EGFR TKI at 17 centers in Korea. Analysis results on the 76 patients with EGFR T790M mutation-positive patients showed that the median overall survival (mOS) was 38.9 months. Ji-Youn Han, Professor of Hemato -Oncology at the National Cancer Center who presented Leclaza’s OS results at the AOS 2022 & KCA Annual Meeting 2022, said, “It is encouraging that the mOS of EGFR T790M mutation-positive patients who are at high risk of brain metastasis had reached 38.9 months in the study, showing over 3 years of survival. Also, Leclaza is associated with the superior effect of achieving median intracranial progression-free survival (mPFS) of 26 months in patients with measurable brain lesions (25 patients).” Han added, “When considering that the ultimate treatment goal of treating cancer patients is in extending life, the OS benefit identified in the trial shows potential to extend life expectancy in T790M mutation-positive patients.” Meanwhile, the latest results of the Phase I/II LASER201 trial had previously been published in the April edition of the Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer (IASLC). Yeol-Hong Kim, Professor of Hemato Oncology at Korea University Anam Hospital, who is also the President of the Asian Oncology Society, said, “It is meaningful that Leclaza’s OS benefit had been presented at the AOS 2022 & KCA Annual Meeting 2022. The fact that Leclaza, a novel homegrown lung cancer drug, has demonstrated an mOS of 38.9 months in the second-line treatment of EGFR mutation-positive NSCLC is remarkable. The results show the possibility that Leclaza could bring a new turning point to the lung cancer treatment landscape in the future.” Wook Je Cho, CEO of Yuhan Corp, said, “We are pleased to share the news that Leclaza showed an OS benefit that meets the expectations as a novel homegrown lung cancer drug. Yuhan Corp will continue to make efforts, including completing the ongoing clinical trials and global commercialization so that Leclaza can become a useful treatment option for patients suffering from EGFR mutation-positive NSCLC in Korea and around the globe. Meanwhile, Yuhan is currently conducting a multinational Phase III trial (LASER 301) to evaluate the efficacy and safety of Leclaza as a first-line treatment in patients with EGFR mutation-positive NSCLC, and the top-line results of the Phase III trial are expected to be disclosed by the end of this year. A global Phase III trial on the combination of Leclaza with amivantamab, Janssen’s fully human bispecific antibody targeting both EGFR and MET, is also in progress.
Company
LG Chem’s Zemiglo+Forxiga combo Zemidapa is approved
by
Chon, Seung-Hyun
Jun 23, 2022 05:50am
LG Chem made a public announcement on the 22nd that the company had received marketing authorization for its type 2 diabetes treatment ‘Zemidapa Tab’ from the Ministry of Food and Drug Safety. The drug is a fixed-dose combination of the antidiabetic drug gemigliptin and dapagliflozin. Gemigliptin is an active ingredient of "Zemiglo," a new DPP-4 inhibitor antidiabetic that was developed by LG Chem. Dapagliflozin is the generic name of AstraZeneca’s SLGT-2 inhibitor, "Forxiga." Zemidapa is the third combination drug made using Zemiglo. LG Chem also owns two other drugs, including ‘Zemimet’ which combines Zemiglo with the antidiabetic drug metformin, and ‘Zemiro’ which combines Zemiglo with the hyperlipidemia drug rosuvastatin, in the market. LG Chem said, “We expect to continue on our current leadership in the diabetes treatment market in Korea with the development of a gemigliptin and dapagliflozin combination that improves the convenience and medication compliance of patients who used to take the two drugs separately as a combination therapy.”
Company
Hyundai Introduces Estrogen-Free Contraceptives
by
Jun 23, 2022 05:50am
Hyundai Pharmaceutical (CEO Lee Sang-joon) announced on the 21st that it has signed an exclusive license agreement with Asuka Pharmaceutical in Korea for the oral contraceptive Slinda"with Drospirenone only. Slinda is a product developed by Exeltis, a women's medical brand division in Insud Pharma, Spain. Unlike the existing fourth-generation complex oral contraceptives, they do not contain Estrogen, so there is less concern about related side effects. Slinda is licensed to sell in the United States and Europe, and Aska has development rights in Korea and Japan. Under this contract, Hyundai Pharmaceutical will have the right to exclusive development and commercialization of Slinda in Korea. An official from Hyundai Pharmaceutical said, "We expect the addition of Slinda to further solidify its position in the domestic contraceptive market."
Company
The third challenge of Imbruvica's primary therapy
by
Eo, Yun-Ho
Jun 22, 2022 05:59am
BTK inhibitor Imbruvica will take on its third challenge to expand insurance benefits. According to related industries, the first-line therapy indication of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) in Imbruvica will be presented again to the HIRA Cancer Disease Review Committee on the 29th. Imbruvica's first-line therapy indication failed to cross the threshold of cancer screening in two challenges, including October last year. Through the PE special system, the benefit was expanded to secondary therapy after registration, but it seems to have faced difficulties in primary therapy. As a result, it remains to be seen what kind of adjustment Janssen will have to discuss expanding benefits. Imbruvica is the first oral BTK (Bruton's Tyrosine Kinase) inhibitor developed once a day, suggesting the advantage of outpatient treatment unlike existing treatments. In Korea, since it was registered in April 2018, it has been prescribed for the second round of ▲ recurrent and refractory chronic lymphocytic leukemia. In addition, it has ▲ indications of Gazyva combination therapy in patients with chronic lymphocytic leukemia who are 65 years of age or older or have a comorbid disease or have a high risk of being treated before, and ▲ treated for chronic lymphocytic leukemia patients who have comorbid diseases over the age of 65 and have never been treated before. Imbruvica proved its survival benefits in CLL patients as a first-line monotherapy through phase 3 studies 'RESONATETM' and 'RESONATETM-2'. All three clinical trials were sponsored by NCI under NIH, and 354 patients with no previous anticancer treatment experience under the average age of 70 were registered in the clinical trial. As a result of 48 months of follow-up observation, 73% of the Imbruvica combined patients continued the Imbruvica treatment for 43 months. In particular, in the Imbruvica combination group, the risk related to PFS was reduced by 61% compared to the current chemotherapy, and the risk was significantly reduced by 66% in OS benefits.
Company
K-botulinum products are expanding globally
by
Jun 22, 2022 05:59am
Hugel Botulex (Letybo) Domestic botulinum toxin is entering various parts of the world. Feeling limited in the domestic market, developers are targeting the U.S., Europe, and China, which are the largest markets in the world, while expanding their scope to countries such as Australia and the Middle East. ◆ Hugel is targeting Europe and North America, and China is expanding its market According to the pharmaceutical industry on the 20th, Hugel won the license for the botulinum toxin drug Letybo developed in Canada on the 16th. It is Hugel's first North American entry. According to Hugel, the Canadian botulinum toxin market is estimated to be worth 180 billion won as of last year. Starting with Southeast Asia, Hugel has attempted to enter Botulinum overseas in earnestly. It is understood that the license registration has been completed in about 40 countries so far. Last year, it applied for permission for Botulinum in the U.S. and Canada to target North America. In particular, the United States is one of the largest botulinum toxin markets worth about 2 trillion won. The U.S. approval, which was originally expected to be approved at the end of March, is expected to take place at the end of this year or early next year. Starting in February, news of Letybo continued in Europe, starting with France. In January, HMA issued a permit recommendation for botulinum. The HMA receives individual decisions in each country after the recommendation for approval, so the date of approval varies. Letybo has obtained product permits from 10 countries, including key European countries such as France, the United Kingdom, Germany, and Italy. ◆Daewoong Nabota Launches Third Quarter in Europe. U.S. Sales Close to 300 Billion Daewoong Pharmaceutical's botulinum toxin drug Nabota is doing good performance in the North American market, which was the first to enter. Nabota posted nearly $100 million in sales last year, up 77.3% from the previous year. This is the result of the North American sales of Daewoong Pharmaceutical's U.S. partner Evolus. Nabota's cumulative sales, which were approved by the U.S. in February 2019, amounted to $223.04 million. In the first quarter of this year, Nabota has continued its upward trend, recording $33.23 million (42.5 billion won), up 171.5% from the previous year. Nabota In the third quarter, Nabota is also set to enter Europe, the second largest market in the world. Evolus, a U.S. partner, will be in charge of sales. Previously, Evolus obtained an item license from the European Commission (EC) in October 2019 under the name Nuceiva. Nuceiva can be sold in 28 countries in the European Union and a total of 31 European countries, including the UK and Switzerland. Daewoong Pharmaceutical recently expanded its scope to Eastern Europe and the Middle East. It has obtained Nabota permission from Saudi Arabia, one of the largest markets in the Middle East, and Ukraine, the representative country of Eastern Europe. Its goal is to expand its market share in the Middle East and Eastern Europe starting with Saudi Arabia and Ukraine. In December last year, Daewoong Pharmaceutical filed an application for permission for Nabota with the NMPA. While Hugel and Daewoong Pharmaceutical are expanding their market to one item developed by themselves, Medy Tox is trying to diversify its products. It was the first in Korea to commercialize botulinum toxin preparations and enter the development of next-generation toxin preparations early. Meditoxin is exported to more than 30 countries around the world under the name Neuronox. However, exports have been decreasing every year since 2019. Overseas exports of Medy Tox, which were 133.3 billion won (including filler products) in 2018, decreased to 120.6 billion won in 2019 and 89.8 billion won in 2020. It recorded 70.6 billion won last year. Neuronox Newlux, which applied for item permission from the MFDS in May, is a new product that Medy Tox applied the latest process to reduce the possibility of contamination by impurities. Medy Tox is also speeding up its overseas licensing work for Newlux exports.
Company
Takeda Korea appoints Sun Jin Lee as head of Oncology BU
by
Jun 21, 2022 05:54am
Sun Jin (Justine) Lee, New Head of Oncology BU, Takeda Pharmaceuticals Korea Takeda Pharmaceuticals Korea (General Manager HeeSeok Moon) announced on the 20th that it had promoted and appointed Manager Sun Jin (Justine) Lee as the Head of its Oncology BU. The new head, Lee, who joined Takeda Pharmaceuticals Korea as a marketing manager of the Hemophilia BU, developed creative marketing strategies and drew participation from internal and external stakeholders for its implementation. Lee played a pivotal role in improving the access and awareness of Takeda Korea's hemophilia business and demonstrated her leadership capabilities. In recognition of her leadership, Lee had led the product launch in the market as a Launch & Digital Excellence Lead in the Asia Pacific (APAC) region, and also successfully carried out projects such as presenting the vision and direction for the digital transformation of Takeda in the APAC region. it was recognized for its leadership capabilities, such as playing a pivotal role in improving the access and awareness of Takeda Korea's hemophilia business. Since then, he has led the product launch in the market as a Launch & Digital Excellence Lead in the Asia Pacific (APAC), and at the same time ha Junghun Kim, the former head of the Oncology BU, has been appointed Country Manager of Malaysia & Singapore in May through the 'FLP(Future Leaders Program)' that provides global networking opportunities for employees within Takeda Pharmaceutical. Kim joined Takeda Pharmaceuticals Korea as a marketing manager in 2015 and established the Inflammatory bowel disease and blood cancer BU. After being appointed head of the Oncology BU in 2019, Lee launched various innovative oncology products in Korea and exceeded the target for three consecutive years, and has been leading the company’s digital transformation in Korea. Under the value ‘Exceptional People Experience,’ Takeda Pharmaceuticals is committed to providing various experiences and opportunities for its employees to develop their capabilities. It also offers special programs for select key talents. The ‘FLP (Future Leaders Program)’, which provides global networking opportunities in Takeda, is one such program, and the recent personnel appointments were also made through the FLP. HeeSeok Moon, General Manager of Takeda Pharmaceuticals Korea, said, “The promotion has more meaning as it was achieved by Takeda’s professional development program. Takeda Pharmaceuticals Korea will continue its best efforts to support various programs for our executives and employees to develop their careers so that each and every employee may realize his or her full potential.”
Company
KIMS has signed a license agreement for Lipothasone
by
Nho, Byung Chul
Jun 21, 2022 05:54am
KIMS Pharmaceutical announced on the 20th that it has signed a contract with Japanese pharmaceutical company Mitsubishi Tanabe Pharma on the 17th to license Lipothasone. Through this contract, KIMS Pharmaceutical will officially release the product in August. According to KIMS Pharmaceutical, Lipothasone is the only Dexamethasone in Korea that uses Mitsubishi Tanabe Pharma's Lipid Nano Particle (LNP) technology. Steroids are excellent enough to be called panacea, but it is a drug that is reluctant to be prescribed due to serious side effects. Lipothasone is known to be a strong and safe anti-inflammatory treatment as well as targeted treatment of inflammatory areas by reducing the side effects of existing steroid injections, allowing IV, Epidural, and Intrathecal. In addition, this product is a drug carrier liposome (liposomalization) using DDS (Drug Delivery System) technology, and is considered to be a product that minimizes drug effect loss and minimizes side effects by selectively expressing effects on target lesions. Kim Seung-hyun, CEO of KIMS Pharmaceutical, said, "We are happy to have LNPS drugs through this contract." "We will continue to strengthen cooperation with Mitsubishi Tanabe Pharma Korea to promote mutual development and do our best to secure patients' access to new drugs," he said. KIMS Pharmaceutical is a company recognized for INNOBIZ, COVA, MAINBIZ, and HBA, and has a corporate research institute and a GMP plant in Osong, Chungcheongbuk-do.
Company
11 of the national essential drugs are non reimbursed
by
Eo, Yun-Ho
Jun 20, 2022 06:04am
It was found that 11 of the drugs designated by The National Essential Medicine, excluding vaccines, are still non-reimbursed. As of December 31, 2021, 511 species have been designated as the National Essential Medicine, and 158 types of infectious disease-related drugs excluding vaccines. Of these, 11 drugs were not on the insurance benefit list. However, Remdesivir, a treatment for COVID-19, is not reimbursed, but the government pays the full cost of the drug. The national essential medicine refers to medicines that must be prepared in the country for national health, and was first discussed and introduced by the World Health Organization. Through the pandemic of infectious diseases such as MERS and COVID-19, securing stable national essential drugs such as vaccines and treatments for preventing infectious diseases is recognized as the core of national security and national competitiveness. However, it is pointed out that the problem of accessibility of the National Essential Medicine is still a blind spot. In fact, the National Health and Welfare Committee's parliamentary audit last year raised questions about the suspension of the supply of The National Essential Medicine and the low health insurance benefit registration rate. Non-payment drugs include Ceftolozane/Tazobactam injections (Zerbaxa), Isabuconazonium sulfate (Cresemba), Baloxavir (Xofluza), which had many clinical demands. Zerbaxa is an antimicrobial drug that was expected to be introduced in Korea as a new treatment alternative to Carbapenem, which was approved in Korea in April 2017 as an indication of complex urinary tract infection and complex intraperitoneal infection by effective strains in adult patients. Carbapenem-resistant-P. aeruginosa is one of the top-priority pathogens that require research and development of new antibiotics. Although Zerbaxa is an effective treatment for resistant bacteria that is not effective for Meropenem, it has been restricted from using Meropenem as an alternative and failed the benefit list despite high demand, but its appropriateness was recognized at the 6th Pharmaceutical Benefit Evaluation Committee held on the 2nd. Cresemba is an antifungal drug that was licensed and non-reimbursed in Korea in January 2020 for invasive aspergillosis and mucormycosis. Like Zerbaxa, it is blocked by PE, which has to prove cost-effectiveness by comparing old drugs with alternatives, and despite the occurrence of COVID-19-related inert aspergillosis in Korea, it is currently non-reimbursed. Invasive aspergillosis is one of the three major invasive fungi threatening humans, which occur in patients with reduced immunity, and is one of the causes of death in immunodeficiency patients due to the recent increase in chemotherapy or AIDS patients in Korea. The flu treatment Xofluza was a new drug that was expected to replace Tamiflu and was approved in Korea in November 2019, just before the COVID-19 pandemic. Since receiving conditional non-reimbursement from the Drug Benefit Evaluation Committee in October 2020, there has been no update yet. The experience of the COVID-19 pandemic has raised awareness of the rapid response of infectious diseases and the importance of drugs in policy and society, while access to infectious diseases, especially new drugs, remains before the pandemic. Since drugs related to severe infectious diseases such as multidrug-resistant infections and invasive fungal infections are used in emergency situations, it is essential to secure various types of drugs so that they can be used immediately if necessary. Choo Eun-joo, director of KSID's Insurance dept. (Professor of Infectious Medicine at Bucheon Hospital at Sooncheonhyang University), said, "There are no antibacterial and antifungal drugs that have been reimbursed for the past five to seven years. As drugs necessary for the treatment of fatal infectious diseases play a key role not only in the survival of individual patients but also in preventing the spread of infectious diseases, they should not be evaluated only from an economic perspective, she said.
<
241
242
243
244
245
246
247
248
249
250
>